Ristocetin

An antibiotic mixture of two components, A and B, obtained from Nocardia lurida (or the same substance produced by any other means). It is no longer used clinically because of its toxicity. It causes platelet agglutination and blood coagulation and is used to assay those functions in vitro.

Also Known As:

Networked: 319 relevant articles (5 outcomes, 25 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Favaloro, Emmanuel J: 4 articles (12/2021 - 11/2007)
2.	Berneman, Zwi: 4 articles (01/2009 - 11/2005)
3.	Gadisseur, Alain: 4 articles (01/2009 - 11/2005)
4.	Schroyens, Wilfried: 4 articles (01/2009 - 11/2005)
5.	Othman, Maha: 3 articles (12/2021 - 09/2013)
6.	Budde, Ulrich: 3 articles (01/2015 - 11/2005)
7.	Michiels, Jan Jacques: 3 articles (01/2009 - 11/2005)
8.	van der Planken, Marc: 3 articles (01/2009 - 11/2005)
9.	Bertomoro, A: 3 articles (03/2002 - 01/2001)
10.	Casonato, A: 3 articles (03/2002 - 01/2001)

Related Diseases

1.	von Willebrand Diseases (von Willebrand's Disease) 10/01/2022 - "Ristocetin dependent cofactor activity in von Willebrand disease diagnosis: Limitations of relying on a single measure." 01/01/2017 - "Whole blood ristocetin-activated platelet impedance aggregometry (Multiplate) for the rapid detection of Von Willebrand disease." 10/01/2015 - "Evaluation of an heterogeneous group of patients with von Willebrand disease using an assay alternative to ristocetin induced platelet agglutination." 04/01/2011 - "The effective diagnosis and monitoring of Von Willebrand Disease (VWD) requires an accurate assessment of ristocetin co-factor activity (VWF:RCo). " 06/01/2005 - "Addition of EMP to plasma from severe von Willebrand disease restored his ristocetin-induced platelet aggregation. "
2.	Actinomycosis 08/01/1988 - "[Therapeutic effectiveness of ristomycin in the visceral form of actinomycosis (experimental research)]." 08/01/1988 - "Therapeutic efficacy of ristomycin in visceral actinomycosis, a severe disease difficult for diagnosis requiring long-term complex therapy was studied on 24 rabbits. " 07/01/1980 - "Ristomycin provides therapeutic concentrations in the disease focus and may produce a satisfactory therapeutic effect in treatment of actinomycosis." 07/01/1980 - "In vitro studies showed that ristomycin was the most active against actinomycetes causing actinomycosis as compared to benzylpenicillin, ampicillin, methicillin and lincomycin. "
3.	Essential Thrombocythemia 07/01/1987 - "Two patients with essential thrombocythemia showed a marked decrease in ristocetin-induced platelet aggregation in addition to other aggregation defects during routine aggregation studies for prolonged bleeding times. "
4.	Endocarditis 12/12/1960 - "[Severe staphylococcal endocarditis cured with ristocetin]." 01/01/1994 - "An investigation was carried out on two patients with infective endocarditis associated with reduction of ristocetin-induced aggregation of platelets. " 01/01/1994 - "Impairment of ristocetin-induced platelet aggregation in patients with infective endocarditis." 11/01/1969 - "[Subacute septic endocarditis successfully treated with ristomycin]." 06/01/1964 - "[PRELIMINARY RESULTS OF THE RISTOMYCIN TREATMENT OF PATIENTS WITH SEPTIC ENDOCARDITIS]."
5.	Sepsis (Septicemia) 05/03/1960 - "[Staphylococcal septicemias treated by ristocetin (spontine)]." 11/13/1958 - "Failure of ristocetin therapy in three cases of staphylococcal sepsis with bacteremia." 01/01/1989 - "By the therapeutic efficacy in albino mice with staphylococcal or streptococcal sepsis eremomycin was 2-4 times as superior as vancomycin and ristomycin and by the chemotherapeutic indices it was more than 10 times as superior." 01/01/2016 - "Platelet secretion induced by collagen, epinephrine, standard and high (10 μM) doses of ADP, or arachidonic acid and platelet aggregation induced by collagen, high-dose ADP, arachidonic acid, ristocetin or thrombin (1 unit) were significantly higher in the sepsis group than in the control group. "

Related Drugs and Biologics

1.	von Willebrand Factor
2.	Factor VIII (Coagulation Factor VIII)
3.	Antigens
4.	Vancomycin
5.	eremomycin
6.	Adenosine Diphosphate (ADP)
7.	Collagen
8.	Epinephrine (Adrenaline)
9.	Arachidonic Acid (Vitamin F)
10.	Coagulants

Related Therapies and Procedures

1.	Therapeutics
2.	Continuous Ambulatory Peritoneal Dialysis (CAPD)
3.	Blood Transfusion (Blood Transfusions)
4.	Intravenous Administration
5.	Subcutaneous Injections